Long-term acid control and proton pump inhibitors: Interactions and safety issues in perspective

American Journal of Gastroenterology

Volumn 92, Issue 4, 1997, Pages

  Freston, James W ^a,b  

^a UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTON PUMP INHIBITOR;

ACHLORHYDRIA; ARTICLE; CANCER RISK; HUMAN; HYPERGASTRINEMIA; INFECTION RISK; PEPTIC ULCER; PRIORITY JOURNAL; PROTON TRANSPORT; STOMACH ACID SECRETION;

ANTACIDS; ANTI-ULCER AGENTS; DRUG INTERACTIONS; GASTRINS; HISTAMINE H2 ANTAGONISTS; HUMANS; PEPTIC ULCER; PROTON PUMPS; SAFETY; TIME FACTORS;

EID: 0030956505     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (25)

1. Freston JW. Overview of medical therapy of peptic ulcer disease. Gastroenterol Clin North Am 1990;19:121-40.
2. Shamburek RD, Schubert ML. Control of gastric acid secretion. Gastroenterol Clin North Am 1992;21:527-50.
3. Bardhan KD. Is there any acid peptic disease that is refractory to proton pump inhibitors? Aliment Pharmacol Ther 1993;7(suppl 1):13-24.
4. Spencer CM, Faulds D. Lansoprazole: A reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid-related disorders. Drugs 1994;48:404-27.
5. Creutzfeldt W, Lamberts R. Is hypergastrinaemia dangerous to man? Scand J Gastroenterol 1991;26(suppl 180):179-91.
6. Freston JW. Clinical significance of hypergastrinaemia: Relevance to gastrin monitoring during omeprazole therapy. Digestion 1992; 51(suppl 1):102-14.
7. Karnes WE, Walsh JH. The gastrin hypothesis: Implications for antisecretory drug selection. J Clin Gastroenterol 1990;12(suppl 2):S7-12.
8. Saltzman JR, Kowdley KV, Pedrosa MC, et al. Bacterial overgrowth without clinical malabsorption in elderly hypochlorhydric subjects. Gastroenterology 1994;106:615-23.
9. Colin-Jones DG. Safety of lansoprazole. Aliment Pharmacol Ther 1993;7(suppl 1):56-60.
10. Nelis GF. Safety profile of omeprazole. Digestion 1989;44(suppl 1): 68-76.
11. Tucker GT. The interaction of proton pump inhibitors with cytochromes P450. Aliment Pharmacol Ther 1994;8(suppl 1):33-8.
12. 450 system have implications to significant drug interactions? Amsterdam, The Netherlands: Elsevier, 1994:460-4.
13. Solvell L. The clinical safety of omeprazole. Digestion 1990;47(suppl 1):59-63.
14. Tolman KG, Sanders SW, Buchi KN. Gastric pH levels after 15 mg and 30 mg of lansoprazole and 20 mg omeprazole. Gastroenterology 1994;106:A172.
15. Lind T, Cederberg C, Olausson M, et al. 24-hour intragastric acidity and plasma gastrin after omeprazole treatment and after proximal gastric vagotomy in duodenal ulcer patients. Gastroenterology 1990; 99:1593-8.
16. Lanzon-Miller S, Pounder RE, Hamilton MR, et al. Twenty-four hour intragastric acidity and plasma gastrin concentration before and during treatment with either ranitidine or omeprazole. Aliment Pharmacol Ther 1987;1:239-51.
17. Brunner G, Arnold R, Hennig U, et al. An open trial of long-term therapy with lansoprazole in patients with peptic ulceration resistant to extended high-dose ranitidine treatment. Aliment Pharmacol Ther 1993;7(suppl 1):51-5.
18. Robinson M, Lanza F, Avner D, et al. Effective maintenance treatment of reflux esophagitis with low-dose lansoprazole: A randomized, double-blind placebo-controlled trial. Ann Intern Med 1996;124:859-67.
19. Klinkenberg-Knol EC, Festen HPM, Jansen JBM, et al. Efficacy and safety of long-term treatment with omeprazole for refractory reflux esophagitis. Ann Intern Med 1994;121:161-7.
20. Borch K, Renvall H, Liedberg G. Gastric endocrine cell hyperplasia and carcinoid tumors in pernicious anemia. Gastroenterology 1985;88: 638-48.
21. Havu N, Maaroos H-I, Sipponen P. Argyrophil cell hyperplasia associated with chronic corpus gastritis in gastric ulcer disease. Scand J Gastroenterol 1991;186(suppl):90-4.
22. Freston JW. FDA presentation of lansoprazole. Advisory Panel on Gastrointestinal Drugs. Rockville, MD, Dec 1, 1994.
23. Lechago J, Correa P. Prolonged achlorhydria and gastric neoplasia: Is there a causal relationship? Gastroenterology 1993;104:1554-7.
24. Penman ID, El-Omar E, Ardill JES, et al. Plasma gastrin concentrations are normal in patients with colorectal neoplasia and unaltered following tumor resection. Gastroenterology 1994;106:1263-70.
25. Logan RP, Walker MM, Misiewicz JJ, et al. Changes in the intragastric distribution of Helicobacter pylori during treatment with omeprazole. Gut 1995;36:12-6.